Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer

Combining cutting-edge AI design and global development expertise to accelerate innovation in oncology drug discovery

Galux today announced a strategic research collaboration with HanAll Biopharma, a global biopharmaceutical company specializing in innovative antibody and protein therapeutics. The partnership aims to co-develop novel antibody therapies for cancer—therapeutics that are difficult to discover using conventional methods.

By combining Galux’s proprietary AI-driven protein design platform with HanAll’s clinical development expertise, the collaboration seeks to engineer precision antibodies that address complex design challenges. The goal is to develop differentiated cancer immunotherapies with enhanced efficacy and reduced toxicity.

“Galux’s proprietary AI protein design technology has the potential to offer fundamentally new solutions to persistent challenges in drug discovery,” said Chaok Seok, CEO of Galux. “We’re excited to partner with HanAll to translate our platform’s capabilities into impactful therapeutic advances.”

GaluxDesign, the company’s AI platform, integrates the fundamental principles of protein physics and chemistry into deep-learning models to design antibodies de novo. Earlier this year, Galux successfully generated antibodies targeting six novel proteins, demonstrating the platform’s exceptional precision, developability, and generalizablity, positioning it among the most advanced AI protein design technologies globally.

HanAll Biopharma brings deep experience in the development of antibody and protein-based therapeutics, with global pipelines across autoimmune diseases, oncology, and ophthalmology. Its lead program, Batoclimab, currently under development for autoimmune indications, was recently granted orphan drug designation in Japan for thyroid eye disease and reported positive Phase 3 results in myasthenia gravis.

The two companies will jointly advance discovery and preclinical validation of next-generation antibody therapeutics through a stepwise collaboration model.

“HanAll has consistently pursued innovation in drug development through the integration of AI technologies,” said Hyekyung Ahn, Head of R&D at HanAll Biopharma. “This collaboration is a strategic extension of that vision, and we look forward to accelerating our R&D efforts through meaningful synergy with Galux.”